Samsung BioLogics faces government auditKorea’s financial regulatory agency said Thursday that it will conduct a special audit on Samsung BioLogics, a biopharmaceutical subsidiary of Samsung Group, over alleged accounting irregularities
The Financial Supervisory Service made the decision on Wednesday, an FSS official said.
The official, who spoke on the condition of anonymity, said the regulator found “unclear parts” in an audit report of Samsung BioLogics, which was revised by the Korean Institute of Certified Public Accountants. The audit report was published before an initial public offering by Samsung Biologics last November.
Samsung BioLogics had been suffering losses since 2011, but reported a net profit of 1.9 trillion won ($1.7 billion) in 2015. Samsung BioLogics said it has yet to receive a notification from the FSS, but it will cooperate with a special audit to clear up “factual grounds.” YONHAP
More in Industry
Eastar Jet's pilot union pushes for receivership of airline
ITC agrees to review its decision in Botox dispute
Hyundai Motor and union come to a wage freeze deal
Samsung Biologics signs supply deal with AstraZeneca
Tesla to increase battery cell purchases from suppliers including LG